News
HAE
86.75
+4.00%
3.34
Don't Overlook These Highly Ranked Medical Stocks as Markets Rise
NASDAQ · 2h ago
Haemonetics' Strategic Moves Poised To Boost Margins And Earnings, Says Analyst
Needham & Co. Analyst Mike Matson upgraded Haemonetics Corporation from Hold to Buy with a price target of $112. The analyst says the company has reaffirmed its “high-20%” operating margin goal for FY26. Matson also says that the company's product mix analysis has bolstered his confidence.
Benzinga · 4h ago
This McCormick Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday
Needham analyst Mike Matson upgraded the rating for Haemonetics Corporation from Hold to Buy. Morgan Stanley upgraded Ciena Corporation from Equal-Weight to Overweight on Tuesday. Citigroup upgraded McCormick & Company, Incorporated from Sell to Neutral and increased the price target.
Benzinga · 8h ago
Haemonetics On Track for Fiscal 2026 Goals: A Buy Rating Backed by Sales Mix and Margin Optimism
TipRanks · 12h ago
Haemonetics Price Target Announced at $112.00/Share by Needham
Dow Jones · 12h ago
Haemonetics Raised to Buy From Hold by Needham
Dow Jones · 12h ago
Needham Upgrades Haemonetics to Buy, Announces $112 Price Target
Benzinga · 12h ago
Weekly Report: what happened at HAE last week (0603-0607)?
Weekly Report · 2d ago
Best Momentum Stocks to Buy for June 6th
NASDAQ · 6d ago
New Strong Buy Stocks for June 6th
NASDAQ · 6d ago
These 3 Companies Boast Bright Outlooks
NASDAQ · 06/04 22:19
Best Momentum Stocks to Buy for June 4th
NASDAQ · 06/04 14:00
Weekly Report: what happened at HAE last week (0527-0531)?
Weekly Report · 06/03 09:02
The total return for Haemonetics (NYSE:HAE) investors has risen faster than earnings growth over the last three years
Haemonetics Corporation is up 54%, over three years, beating the market return of 12%. Haemonetics has shed US$188m from its market cap this week. The company has been able to grow its earnings per share at 14% per year over the last three years. The share price has also grown with the company over the same period. Haemonetic has beaten the market returns of 12% over the past year.
Simply Wall St · 05/31 12:40
3 Highly Ranked Medical Stocks Added to the Zacks Strong Buy List
NASDAQ · 05/28 22:53
Best Momentum Stocks to Buy for May 28th
NASDAQ · 05/28 14:00
3 Reasons Why Growth Investors Shouldn't Overlook Haemonetics (HAE)
NASDAQ · 05/27 16:45
Weekly Report: what happened at HAE last week (0520-0524)?
Weekly Report · 05/27 09:02
Wall Street Analysts Believe Haemonetics (HAE) Could Rally 26.58%: Here's is How to Trade
NASDAQ · 05/24 13:55
Haemonetics Corp Mass: Statement of changes in beneficial ownership of securities
Press release · 05/23 14:24
More
Webull provides a variety of real-time HAE stock news. You can receive the latest news about Haemonetics Corp Mass through multiple platforms. This information may help you make smarter investment decisions.
About HAE
Haemonetics Corporation is a global healthcare company. The Company is engaged in providing a suite of medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Its technology addresses various medical markets, including blood and plasma component collection, the surgical suite, and hospital transfusion services. The Company’s Plasma segment includes plasma collection devices and disposables, donor management software and supporting software solutions sold to plasma customers. Its Blood Center segment includes blood collection and processing devices and disposables for red cells, platelets and whole blood. The Company’s Hospital segment consists of Interventional Technologies, which includes vascular closure devices and sensor-guided technologies, and Blood Management Technologies, which includes devices and methodologies for measuring coagulation characteristics of blood, and blood transfusion management software, among others.